Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7765030 | 1.00 | LMNA (0.58) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4674018 | 0.89 | LMNA (0.60) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4674019 | 0.89 | LMNA (0.60) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4670789 | 0.86 | LMNA (0.56) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL6267900 | 0.86 | LMNA (0.56) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL7507913 | 0.85 | LMNA (0.55) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4670734 | 0.85 | LMNA (0.58) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4675511 | 0.82 | LMNA (0.52) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL7500686 | 0.81 | LMNA (0.53) | LMNATP53MAPTL3MBTL1MGLL | |
| SCHEMBL4673603 | 0.77 | LMNA (0.51) | LMNATP53MAPTL3MBTL1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |